A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
Christina D. Drenberg(The Ohio State University), Sharyn D. Baker(The Ohio State University)
Cited by 41
Related Papers
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)
|Pediatric Blood & Cancer|2017|73
Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD–Positive AML
|Molecular Cancer Therapeutics|2021|45
Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia
|Journal of Clinical Investigation|2017|39